Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Head & Neck 1

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 92Carcinoma, Non-Small-Cell Lung 77Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 64Glioma 59Pancreatic Neoplasms 45Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 38Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 32Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

Indocyanine Green 7Radiotherapy 4Magnetic Resonance Spectroscopy 4Lymph Node Excision 4Cisplatin 4Surgical Procedures, Operative 3Specimen Handling 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3gadofosveset trisodium 2Technetium 2TP protocol 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Nivolumab 2Ipilimumab 2Electroporation 2Conversion to Open Surgery 2Control Groups 2tislelizumab 1radium Ra 223 dichloride 1peposertib 1pembrolizumab 1gewf solution 1encorafenib 1cabozantinib 1binimetinib 1avelumab 1alovudine 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lymphatic Metastasis × Magnetic Resonance Spectroscopy × Clear all
NCT03793166 2026-05-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,175 enrolled
Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT05075980 2026-04-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Mayo Clinic

Phase 2 Active not recruiting
174 enrolled
Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT06527027 2025-12-30

LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes

Copernicus Memorial Hospital

Phase NA Recruiting
1,000 enrolled

Lymphadenopathy, Lymphatic Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡